Drug Trial Radar · NCT02724163
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Apr 2016
Primary completion
Dec 2031
Study completion Dec 2032
Sponsor
- Lead sponsor
- University of BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Assistance Publique - Hôpitaux de Paris; Cancer Research UK; National Cancer Institute, France; Pfizer
- First posted
- Mar 31, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is : 1. To establish which number of doses of gemtuzumab ozogamicin (up to a maximum of 3 doses) is tolerated and can be safety delivered in combination with cytarabine plus mitoxantrone or liposomal daunorubicin in induction 2. To compare mitoxantrone (anthracenedione) \& cytarabine with liposomal daunorubicin (anthracycline) \& cytarabine as induction therapy. (Randomisation 1 (R1) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.) 3. To compare a single dose of gemtuzumab ozogamicin with the optimum tolerated number of doses of gemtuzumab ozogamicin (identified by the dose-finding study) when combined with induction chemotherapy. 4. To compare two consolidation regimens: high dose cytarabine (HD Ara-C) and fludarabine \& cytarabine (FLA) in standard risk patients. 5. To compare the toxicity and effectiveness of two haemopoietic stem cell transplant (HSCT) conditioning regimens of different intensity: conventional myeloablative conditioning (MAC) with busulfan/cyclophosphamide and reduced intensity conditioning (RIC) with fludarabine/busulfan.
Conditions
- Acute Myeloid Leukaemia
Interventions
Gemtuzumab ozogamicinDrug
Antibody-conjugated chemotherapy agent.
Liposomal daunorubicinDrug
Anthracycline (Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.
MitoxantroneDrug
DNA-reactive agent
FludarabineDrug
A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
CytarabineDrug
Pyrimidine nucleoside analogue, an antineoplastic agent.
BusulfanDrug
Alkylsulfonate
CyclophosphamideDrug
A nitrogen mustard alkylating agent from the oxazaphosphorine group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs).Time frame: Incidence of DLTs will be evaluated up to day 45 post course 1 and course 2 of induction chemotherapy.
- Event Free Survival (EFS).Time frame: Event free survival (EFS) will be evaluated as the time from randomisation one to the first event, up to 16 years.
- Event Free Survival (EFS).Time frame: Event free survival (EFS) will be evaluated as the time from randomisation two to the first event, up to 16 years..
- Relapse free survival (RFS).Time frame: Relapse free survival (RFS) will be evaluated as the time of randomisation three to the first relapse or death from any cause, up to 16 years.
- Early treatment related adverse reactions.Time frame: Early treatment related adverse reactions will be evaluated at day 100 post-transplant.
- Relapse free survival (RFS).Time frame: Relapse free survival (RFS) will be evaluated as the time of randomisation four to the first relapse or death from any cause, up to 16 years.
Locations
68 sites in 6 countries. Site status is shown where the registry gives one.
Women and Children's Hospital Adelaide
Adelaide, Australia
Queensland Children's Hospital
Brisbane, Australia
Monash Children's Hospital
Melbourne, Australia
Royal Childrens Hospital
Melbourne, Australia
John Hunter Children's Hopsital
New Lambton Heights, Australia
Perth Children's Hospital
Perth, Australia
Sydney Children's Hospital
Sydney, Australia
The Childrens Hospital At Westmead
Westmead, Australia
Centre Hospitalier Universitaire Amiens - Picardie
Amiens, France
Centre Hospitalier Universitaire D'angers
Angers, France
Centre Hospitalier Regional Universitaire Besancon - Hopital Jean Minjoz
Besançon, France
Centre Hospitalier Universitaire De Bordeaux - Hopital Pellegrin
Bordeaux, France
Centre Hospitalier Regional Universitaire Brest - Hopital Morvan
Brest, France
Centre Hospitalier Universitaire De Caen
Caen, France
Centre Hospitalier Universitaire De Clermont-ferrand
Clermont-Ferrand, France
Centre Hospitalier Universitaire Dijon Bourgogne - Hopital D'enfants
Dijon, France
Centre Hospitalier Universitaire De Grenoble
Grenoble, France
Hopital Jeanne Dr Flandre
Lille, France
Centre Hospitalier Universitaire De Limoges
Limoges, France
Centre Leon Berard
Lyon, France
Hopital De La Timone
Marseille, France
Centre Hospitalier Regional Universitaire Montpellier - Hopital Arnaud-de-villeneuve
Montpellier, France
Centre Hospitalier Universitaire De Nancy
Nancy, France
Centre Hospitalier Universitaire De Nantes
Nantes, France
Centre Hospitalier Universitaire De NICE
Nice, France
Hopital Armand Trousseau
Paris, France
Hopital Robert Debre
Paris, France
Hopital Saint Louis
Paris, France
Centre Hospitalier Universitaire De Poitiers
Poitiers, France
Chu De Reims
Reims, France
Centre Hospitalier Universitaire De Rennes - Hopital Sud
Rennes, France
Centre Hospitalier Universitaire De Rouen
Rouen, France
Centre Hospitalier Universitaire Saint-etienne
Saint-Etienne, France
Strasbourg Hautepierre
Strasbourg, France
Centre Hospitalier Universitaire De Toulouse - Hopital Des Enfants
Toulouse, France
Centre Hospitalier Regional Universitaire De Tours - Hopital Clocheville
Tours, France
Our Lady's Hospital for Sick Children
Dublin, Ireland
Starship Childrens Hospital
Auckland, New Zealand
Christchurch Hospital
Christchurch, New Zealand
Kantonsspital Aarau
Aarau, Switzerland
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.